6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino]nicotinic acid | 1337469-50-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino]nicotinic acid
• 英文别名: (E)-6-(Ethyl(5-isobutoxy-4-isopropyl-2-styrylphenyl)amino)nicotinic acid；6-[N-ethyl-5-(2-methylpropoxy)-2-[(E)-2-phenylethenyl]-4-propan-2-ylanilino]pyridine-3-carboxylic acid
• CAS: 1337469-50-7
• 化学式: C₂₉H₃₄N₂O₃
• 分子量: 458.601
• InChiKey: LJBCFPFVWAAOMP-OUKQBFOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 6-[N-ethyl-N-(3-isobutoxy-4-isopropylphenyl)amino]nicotinate 在 碘 、 palladium diacetate 、 silver sulfate 、 三乙胺 、 三(邻甲基苯基)磷 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 84.0h， 生成 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino]nicotinic acid
  参考文献：
  名称：

  Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB

  摘要：

  We discovered a potent retinoid X receptor (RXR) antagonist, 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino]nicotinic acid (13e), that is structurally closely related to the RXR full agonist 6-[N-ethyl-N-(3-isobutoxy-4-isopropylphenyl)amino]nicotinic acid (NEt-3IB) (4). Compound 13e was synthesized via a simple route from 11, a methyl ester precursor of 4. Because 11 possesses high electrophilic reactivity because of the amino and alkoxy groups, it was readily transformed to 12 by iodization, and the iodine atom of 12 was converted to a C-C or C-N bond by means of palladium-catalyzed reaction to afford 13. Transcriptional activation assay revealed that 13g (in which the iodine atom was replaced with an amino group) is a weak RXR agonist, while 13d (a phenyl group), 13e (a styryl group), and 13f (an anilino group) are RXR antagonists. Among them, 13e was found to be more potent than the known RXR antagonist PA452 (9).

  DOI：

  10.1021/ml200197e

文献信息

• [EN] p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE<br/>[FR] INHIBITEUR DE PI6INK4A DESTINÉ À PRÉVENIR OU À TRAITER LA MALADIE DE HUNTINGTON
  申请人：UNIV SORBONNE

  公开号：WO2020212597A1

  公开（公告）日：2020-10-22

  The present invention relates pl6INK4a inhibitor, a composition of a pharmaceutical composition, for use in preventing and/or treating Huntington's disease, wherein said inhibitor is a nucleic acid or a peptide, a small compound molecule or a marketed drug.
• Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB
  作者：Mariko Nakayama、Shoya Yamada、Fuminori Ohsawa、Yui Ohta、Kohei Kawata、Makoto Makishima、Hiroki Kakuta

  DOI：10.1021/ml200197e

  日期：2011.12.8

  We discovered a potent retinoid X receptor (RXR) antagonist, 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(E)-styrylphenyl)amino]nicotinic acid (13e), that is structurally closely related to the RXR full agonist 6-[N-ethyl-N-(3-isobutoxy-4-isopropylphenyl)amino]nicotinic acid (NEt-3IB) (4). Compound 13e was synthesized via a simple route from 11, a methyl ester precursor of 4. Because 11 possesses high electrophilic reactivity because of the amino and alkoxy groups, it was readily transformed to 12 by iodization, and the iodine atom of 12 was converted to a C-C or C-N bond by means of palladium-catalyzed reaction to afford 13. Transcriptional activation assay revealed that 13g (in which the iodine atom was replaced with an amino group) is a weak RXR agonist, while 13d (a phenyl group), 13e (a styryl group), and 13f (an anilino group) are RXR antagonists. Among them, 13e was found to be more potent than the known RXR antagonist PA452 (9).